Lexicon Pharmaceuticals, Inc. (LXRX): James F Tessmer , VP, Finance & Accounting of Lexicon Pharmaceuticals, Inc. sold 1,500 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $15.00 per share for a total value of $22,500.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 23, 2016, James F Tessmer (VP, Finance & Accounting) sold 6,000 shares at $13.00 per share price.
Shares of Lexicon Pharmaceuticals (LXRX) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -0.47 points or -3.11% at $14.64 with 4,64,140 shares getting traded. Post opening the session at $14.89, the shares hit an intraday low of $14.55 and an intraday high of $15.07 and the price vacillated in this range throughout the day. The company has a market cap of $1,520 M and the number of outstanding shares has been calculated to be 10,38,21,416 shares. The 52-week high of Lexicon Pharmaceuticals is $15.79 and the 52-week low is $7.42.
Lexicon Pharmaceuticals Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company’s sotagliflozin is an orally delivered small molecule drug candidate as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.